ZYTOMICS
LIVE

Serial Number

79391171

Owner

ZytoVision GmbH

Attorney

Laurence P. Colton

Filing Date

Nov 1, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ZYTOMICS Trademark

Serial Number: 79391171 • Registration: 8081487

ZYTOMICS is a trademark filed by ZytoVision GmbH on November 1, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

ZytoVision GmbH (6 trademarks)

Fischkai 1

Entity Type: 99

Trademark Details

Filing Date

November 1, 2023

Registration Date

December 30, 2025

Published for Opposition

November 11, 2025

Goods & Services

Medical apparatus and instruments for use in cancer diagnostic and treatment procedures; medical instruments for use in cancer diagnostic and treatment procedures; medical analytical apparatus for analyzing human cells and tissues for the presence of cancerous cells for medical purposes; automatic analyzers for medical diagnosis of cancer in human cells and tissues; physical analyzers for diagnosing cancer for medical use; genetic testing apparatus for medical purposes

Medical services; medical diagnostic services; medical in-vitro diagnostic services for medical and pharmaceutical purposes; medical services in the fields of pathology, genetic science, human genetics, molecular pathologies, molecular biology, microbiology, biotechnology and laboratory medicine; medical diagnostic services using histology, cytology, immunohistology, immunohistochemistry, in situ hybridisation, polymerase chain reaction (PCR), next generation sequencing (NGS), microarray hybridisation in the nature of genetic chip or biochip hybridisation, flow cytometry and isolation of biomolecules including DNA, RNA and proteins; medical counseling; pharmaceutical services in the nature of pharmaceutical advice in the field of diagnosing and treating cancer; pharmaceutical advice; medical and health clinic services relating to DNA, genetics and genetic testing; medical pathology services; genetic testing for medical purposes

Chemicals for use in industry and science; chemicals and biochemicals for use in science in the fields of pathology, genetics, human genetics, molecular pathologies, molecular biology, microbiology, biotechnology, laboratory medicine; chemicals and biochemicals for use in science in the fields of histology, cytology, immunohistology, immunohistochemistry, in situ hybridisation, polymerase chain reaction (PCR), next generation sequencing (NGS), microarray hybridisation in the nature of genetic chip or biochip hybridisation, flow cytometry services, and isolation of biomolecules including DNA, RNA and proteins; nucleic acids in the nature of DNA, RNA, oligonucleotides, polynucleotides, marked nucleic acids and modified nucleic acids, for scientific purposes; proteins in the nature of peptide substrates, recombinant proteins and marked proteins for scientific and medical research; antibodies for scientific purposes; DNA probes being biochemical preparations for scientific purposes; RNA probes being biochemical preparations for scientific purposes; oligonucleotide probes being biochemical preparations for scientific purposes; biological tissue, namely, human stem cells, human somatic cells, human cancer cells, human tissue, human tissue sections, for scientific and medical research; nucleic acids, proteins, human somatic cells, human cancer cells, and stem cells immobilised on carriers for scientific and medical research

Pharmaceuticals and medical preparations for use in chemotherapy and cancer diagnostics; diagnostic preparations for medical purposes; diagnostic preparations for in-vitro testing for medical use; pharmaceuticals, pharmaceutical preparations, medical products in the nature of diagnostic preparations, medical preparations, chemical products in the nature of chemical reagents, chemical preparations, biochemical products in the nature of chemical reagents, and biochemical preparations, all for use in chemotherapy and cancer diagnostics for medical use; pharmaceutical, medical, chemical and biochemical preparations for medical purposes in the fields of histology, cytology, immunohistology, immunohistochemistry, in situ hybridisation, polymerase chain reaction (PCR), next generation sequencing (NGS), microarray hybridisation in the nature of genetic chip or biochip hybridisation, flow cytometry services, and isolation of biomolecules including DNA, RNA and proteins; nucleic acids in the nature of DNA, RNA, oligonucleotides, polynucleotides, marked nucleic acids and modified nucleic acids for medical purposes; proteins in the nature of peptide substrates, recombinant proteins and marked proteins for use in chemotherapy and cancer diagnostics for medical purposes; antibodies for medical purposes; DNA probes being biochemical preparations for chemotherapy and cancer diagnostics for medical use; RNA probes being biochemical preparations for chemotherapy and cancer diagnostics for medical use; oligonucleotide probes being biochemical preparations for chemotherapy and cancer diagnostics for medical use; biological tissue, namely, human stem cells, human somatic cells, human cancer cells, human tissue, and human tissue sections for use in chemotherapy and cancer diagnostics; nucleic acids, proteins, human somatic cells, human cancer cells and human stem cells immobilised on carriers for medical diagnostic purposes

Science and technology services, namely, research in the field of cancer; medical research laboratory services; development of pharmaceutical preparations and medicines; clinical research in the field of cancer diagnosis and treatment for medical and scientific purposes; research relating to biotechnology; scientific research consultancy services; biological analysis, biochemical analysis, chemical analysis, scientific analysis, all being scientific research; scientific research in the field of genetics and genetic engineering

Business management consultancy and advisory services; operation of a business for others, namely, holding company services performed for third parties in the nature of business management and business administration of subsidiaries, business management of medical and biotechnology companies, and business administration of research and development organizations; holding company services performed for third parties, namely, business management, business administration, providing office functions; holding company services performed for third parties, namely developing marketing strategy, professional business and organisational consultancy and management of the business interests of others and legally independent companies; business management and organization consultancy; advisory services for business management; business administration; providing office functions; planning and monitoring of business developments with regard to organisational matters in the nature of business organisational consultation

Scientific research and laboratory apparatus in the nature of analysis systems, comprised of automated slide staining instruments, automated laboratory instruments for slide assembly, staining, labeling, and incubation, sample preparation instruments in the nature of automated sample processing instruments, and liquid handling robots, non-medical imaging devices for proteins, nucleic acids, human cells, and human tissues, robotic sample handling systems being laboratory robots, microscopes, spectrophotometers, thermal cyclers, flow cytometers, and computer hardware with recorded software and downloadable software for conducting and evaluating laboratory procedures for use in the analysis of proteins, nucleic acids, human cells, and human tissues; educational apparatus and simulators in the nature of medical diagnostic simulators for use as teaching aids for medical procedures; analysis apparatus in the nature of diagnostic apparatus for research laboratory use for conducting and evaluating histology, cytology, immunohistology, immunohistochemistry, in situ hybridisation, polymerase chain reaction (PCR), next generation sequencing (NGS), microarray hybridisation in the nature of genetic chip or biochip hybridisation, flow cytometry, and isolation of biomolecules including DNA, RNA and proteins; research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; analysis apparatus for research laboratories in the nature of diagnostic apparatus for measuring, testing and examining tissue, cells and biomolecules including DNA, RNA and proteins

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 30, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 30, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 30, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 11, 2025 PUBO
NEW REPRESENTATIVE AT IB RECEIVED
Nov 6, 2025 NREP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 8, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 8, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 8, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 8, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 8, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 30, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 30, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 15, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 15, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 15, 2025 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sep 10, 2025 ZZZX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 29, 2025 OPNX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Aug 26, 2025 PBCR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 13, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 13, 2025 OPNR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 31, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 31, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 31, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 31, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 31, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 6, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 6, 2025 TROA
REFUSAL PROCESSED BY IB
Feb 9, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 22, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jan 22, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 27, 2024 RFCR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 4, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 4, 2024 COAR
NON-FINAL ACTION WRITTEN
May 31, 2024 CNRT
ASSIGNED TO EXAMINER
May 30, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 24, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 22, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 14, 2024 REPR